2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
- 20 October 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1082